Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

AstraZeneca (AZN) says there were "no reports of opioid withdrawal" that could be attributed to...

  • Tuesday, February 26, 8:31 AM ET
    AstraZeneca (AZN) says there were "no reports of opioid withdrawal" that could be attributed to its Naloxegol laxative in a fourth Phase III trial. AZN and partner Nektar Therapeutics (NKTR) will use the outcome to obtain decontrol of naloxegol, which is considered a Schedule II controlled substance by the DEA. With the testing demonstrating other "high-level" safety results, AstraZeneca plans to file for FDA and EU approval of Naloxegol in Q3. (PR)
Track new comments on this story

This news story has 1 comment:

  •  
    I was wondering how much anticipated AZN revenue could be realized by Naloxegol . It this an exclusively AZN patented drug?

    Thanks, Thirsty
    26 Feb, 03:19 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »